E
Envision Healthcare Clinical Research | Nashville, TN
Research site
(Unclaimed)
Site insights
Top conditions
Top treatments
Ranibizumab
EYE103
Aflibercept
Curious how this site stacks up to its peers?
Data sourced from clinicaltrials.gov
Work at this site?
CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.
Active trials
3 of 5 total trials
New
EYE-RES-104 is a randomized, dose-masked study of intravitreal EYE103 in participants with neovascular age-related macular degeneration (NVAMD) or ma...
Enrolling
Neovascular Age-Related Macular Degeneration (NVAMD)
Branch Retinal Vein Occlusion (BRVO)
Drug: EYE103
Drug: Aflibercept 2.0 mg
EYE-RES-103 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of EYE103 in comparison with the active...
Enrolling
Diabetic Macular Edema (DME)
Drug: EYE103
Drug: Ranibizumab
EYE-RES-102 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of EYE103 in comparison with the active...
Active, not recruiting
Diabetic Macular Edema (DME)
Drug: EYE103
Drug: Ranibizumab
Trial sponsors
E
Clinical trials
Research sites
Resources
Legal
© Copyright 2025 Veeva Systems